

This is one of the inside challenge page it uses the same squares layout from the homepage only its populated with many



replace with search button
here and use the search page i
sent to filter results



NORTHWESTERN UNIVERSITY ...

Every 15 seconds, an American suffers a traumatic brain injury (TBI), hospitalizing 230,000 Americans annually at a cost of more than \$50 billion. Patients are typically classified as mild, moderate or severe depending on the extent of injury. Because of a lack of specific therapies for TBI, patients hospitalized with moderate injuries receive care consisting

 83 LIKES

[READ MORE](#) [SHARE](#)



CONCORDIA UNIVERSITY - 14.A

Market • About 20% of all MRI examinations are subject to patient movement, costing over \$1B/year in rescans across 11,000 MRI machines in North America. Company Objectives • MotionCorrect makes MRI scans simpler and shorter for patients by using a visual tracking system to compensate for movement in real-time. • Our platform increases

 52 LIKES

[READ MORE](#) [SHARE](#)



TULANE UNIVERSITY - 8.A

COMPANY OVERVIEW NOLA Therapeutics develops cancer drug treatments using nanotechnology and antibody therapy. CORE TEAM Technical Michael Strong, MD/PhD candidate James Morgan Dixon, MS Biomedical Engineering, MBA candidate Gary Mouradian, PhD, Postdoctoral fellow Juan Carlos Vera, MD, MS candidate in Clinical Research

 135 LIKES

[READ MORE](#) [SHARE](#)



WAKE FOREST UNIVERSITY - 1...

EncepHeal Therapeutics develops products based on innovative and unique neuroscience research. We are a CNS therapeutic company focused on early stage development with a goal of creating lucrative pharmaceutical collaborations. Our lead product (ECH-201) targets individuals who are either currently suffering from or are at a significant risk

 50 LIKES

[READ MORE](#) [SHARE](#)



HKCCN - 3.B

Please click this link for easy-read access: <https://claremontmkenna.box.com/s/0016kj2npxv7>

BDCare is a startup pharmaceutical company specializing in developing the drug NtBuIA that can potentially cure the fatal Infantile Neuronal Ceroid Lipofuscinosis (INCL) disease. The target customers are all INCL affected orphans and their affiliates. The

 24 LIKES

[READ MORE](#) [SHARE](#)



TULANE UNIVERSITY - 1.A

Attention-deficit/hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 6.4M children between 4-17 years of age. Approximately 3.55M of these children are currently receiving medication to treat the symptoms of ADHD contributing to the \$6.9B global market in 2013. Historically, the most common medications prescribed for the treatment

 54 LIKES

[READ MORE](#) [SHARE](#)



UNIVERSITY OF ROCHESTER- ...

Glioblastoma is the most common and lethal cancer of the central nervous system, affecting hundreds of thousands of patients each year. Current diagnostic tools for glioblastoma require potentially dangerous biopsies and cost-intensive imaging. Existing therapeutic approaches are limited, with 95% of patients dying within five years. Our company,

 131 LIKES

[READ MORE](#) [SHARE](#)



MCGILL-8.A

Gliomacare Inc., helps clinicians to diagnose brain tumor from patients presenting with minimal symptoms. Using a comprehensive blood based biomarker bio-chip test, the company aims to provide an inexpensive and an easy to integrate method to screen brain tumors at an early stage. By developing an easy-to-integrate, quick and an

 41 LIKES

[READ MORE](#) [SHARE](#)



UNIVERSITY OF TEXAS HEALT...

Protemgem is a development-stage biopharmaceutical company pursuing a pipeline of peptide-based therapeutics with an initial focus on Alzheimer's disease (AD). AD is an incurable disorder, affecting more than 5 million Americans with healthcare costs of over \$200 billion annually. Product/Technology Encouraged by earlier favorable

 309 LIKES

[READ MORE](#) [SHARE](#)



UNIVERSITY OF ROCHESTER 1...

Artifix has developed a technology that can vastly improve motion correction in medical imaging. The most common reason for motion 'blurring' artifacts in MRI images is also fairly inevitable. Staying motionless in a noisy and confined space for an extended period of time is not an easy task for a healthy individual let alone a patient or a child being

 119 LIKES

[READ MORE](#) [SHARE](#)



WAKE FOREST UNIVERSITY - 4...

Overview We are at the forefront of developing targeted therapies, enabling people to function more naturally in society. We do this by producing a highly selective drug, named MLS21, which alleviates brain mismanagement of dopamine without producing side effects that disrupt their lives. Dopamine plays a major role in the regulation of

 30 LIKES

[READ MORE](#) [SHARE](#)



JHU-6.B

Opportunity: >In 2010, over 2.5M Americans visited the ER or were hospitalized due to traumatic brain injury (TBI) >More than 100,000 players of contact sports suffer from TBI each year >Lack of immediate medication post-injury leaves the brain susceptible to the damaging effects of secondary inflammation, which may account for high incidence of dementia

 13 LIKES

[READ MORE](#) [SHARE](#)



TULANE UNIVERSITY - 7.A

Innovative Vascular Therapeutics (IVT) is a company based in New Orleans working towards developing the first line of novel stroke therapeutics. Stroke is the 4th leading cause of death in the United States, claiming over 130,000 lives annually. For the majority of stroke victims, this event imposes a \$200,000 cost over the course of their lives, and

34 LIKES

[READ MORE](#)[SHARE](#)

WASHINGTON UNIVERSITY IN ...

Pro-Arc Diagnostics offers an assay for the presence of virulent and non-virulent JC virus (JCV), allowing patients to safely receive monoclonal antibody (mAb) therapy. 50% of people in the US carry JCV, which is usually non-virulent. However, JCV spontaneously mutates into its virulent form in 30% of carriers. In a small percentage of these carriers,

59 LIKES

[READ MORE](#)[SHARE](#)

CUMC-9.A

Avastin is a monoclonal antibody that nonspecifically inhibits angiogenesis. It currently sells \$6.5B annually and is effective for the first- and second-line combination treatment of multiple forms of advanced cancers, including brain tumors. Off-target and systemic adverse effects such as bleeding and impaired wound healing in normal

449 LIKES

[READ MORE](#)[SHARE](#)

UNIVERSITY OF CHICAGO - 1.A

Cortexius Corp. is developing safer, effective CNS therapeutics needed to improve treatments for neurological disorders and provide better, more active lives for our patients. Business Summary Cortexius Corp. is a research and development pharmaceutical company addressing the need for improved, non-stimulatory treatments to manage

3 LIKES

[READ MORE](#)[SHARE](#)

UPENN - 6.A

Company Overview: Neurono is developing a device via which small molecular (<40,000 MW) therapeutics can diffuse through the skull into brain parenchyma. This technology will have a wide array of applications (e.g. inflammatory CNS processes). The relevant intellectual property will be in-licensed from the NIH. Competitive Analysis: This process is

72 LIKES

[READ MORE](#)[SHARE](#)

WAKE FOREST UNIVERSITY 16.J

TAQ Technologies (TT) is a biotech company working to commercialize a targeted, affordable, quick diagnostic test to detect the John Cunningham virus (JCV). While latent in nearly 70% of the US population, in severely immunocompromised patients, JCV can become active and cause the lethal neurological disorder progressive multifocal

196 LIKES

[READ MORE](#)[SHARE](#)

ILLINOIS INSTITUTE OF TECH...

Great Lakes Neuroscience (GLN) is a privately held company developing therapies for neurodegenerative diseases. GLN has a strong, well-qualified team with experience in research, product development, clinical trials, and current good manufacturing practices. Our Scientific Advisory Board is composed of experts from companies

234 LIKES

[READ MORE](#)[SHARE](#)

THOMAS JEFFERSON UNIVER...

ImmunoMark is developing antibody-drug conjugates (ADC) for the treatment of brain cancer. Problem Despite advances in conventional therapies, brain cancer prognosis is still very poor. Of the 70,000 people diagnosed with brain tumors annually, only 13% reach 10-year survival. Surgery and radiation are invasive and cause off-target

200 LIKES

[READ MORE](#)[SHARE](#)

engineering a better tomorrow

NÜROS (UCSF-#6)

At nuros, our mission is to revolutionize drug delivery to the brain. We aim to provide a viable treatment option for traumatic brain injury (TBI) and concussion. The platform can be leveraged to deliver drugs for strokes and other neurological disorders in the future. Our initial technology, to be branded nūpass™, will be developed as a first-ever

32 LIKES

[READ MORE](#)[SHARE](#)

YALE UNIVERSITY - 2.A

Test

0 LIKES

[READ MORE](#)[SHARE](#)

Alzheimer's

Temporada Pharmaceuticals is committed to finding breakthrough alternatives for the early diagnosis and treatment of Alzheimer's disease through the development of TFP5 (Invention 2). With a unique blend of dedication, skill, and experience

52 LIKES

[READ MORE](#)[SHARE](#)

UNIVERSITY OF TEXAS AT HO...

There are more than 90,000 patients currently living with Neurofibromatosis Type I (NF1) in the USA. NF1 is a genetic disease caused by the malfunction of neurofibromin, a regulatory protein. Most of the patients develop benign tumors that can be removed by surgery. However, 1 in 20 will develop malignant tumors, such as malignant peripheral

108 LIKES

[READ MORE](#)[SHARE](#)

MCGILL UNIVERSITY - 16.A

At Vigilance Diagnostics, we believe the best treatment decisions are those informed by an accurate assessment of therapeutic benefits and risks. While several immunomodulating therapeutics are effective in managing chronic auto-immune disorders, such as Multiple Sclerosis (MS), in some instances, patients have contracted the often fatal

204 LIKES

READ MORE

SHARE

MCGILL-16.B

Cephalocare Inc., offers an inexpensive and rapid DNA based chip technology to identify virulent forms of John Cunningham virus (JCV) that causes Progressive multifocal leukoencephalopathy (PML). Multiple Sclerosis (MS) treatment drugs, Tysabri and Avonex, have shown to activate the virulent forms of JCV. Cephalocare Inc will help clinicians segregate

42 LIKES

READ MORE

SHARE

UNIVERSITY OF ALABAMA - 1.A

According to the National Institute of Health, 23.2 million Americans are trapped in detrimental addictions. Addictions affect not only the addict, but also family, friends, and even strangers. With this behavior costing the U.S. over \$600 billion each year, and harming loved ones every day, consider this a nationwide call to action. Crimson Pharma is a

88 LIKES

READ MORE

SHARE

DUKE UNIVERSITY - 15.A

A median survival rate of 14.6 months underscores the desperate need for effective treatments of the brain tumor glioblastoma multiforme (GBM), as well as other deadly cancers. Such an advance is possible using the work of Drs. Zabow and Koretsky, whose multimodal MRI contrast agent based on magnetic microstructures enables differential

9 LIKES

READ MORE

SHARE

UNC CHAPEL HILL - 6.A

Traumatic brain injury (TBI) is a \$76 billion dollar problem. Each year there are over 50,000 deaths and 1.8M patients diagnosed with TBI in the US alone. ShiraDevices offers a solution to this problem through our revolutionary Brain Balm delivery system (patent pending). Brain Balm is an easy, preloaded disposable injection of a hydrogel

34 LIKES

READ MORE

SHARE

BUCKEYE SMARTERIMAGE - 14...

Patient movement is the single largest contributor to image acquisition time, reread rate, and image quality degradation in brain MRI. This costs the US healthcare system \$6.3B annually, of which \$2.8B is carried directly by our customers—hospitals and imaging clinics. What do we offer? Buckeye SmarterImage (BSI) offers a patent-pending motion

22 LIKES

READ MORE

SHARE

Management Team



• Doctoral backgrounds
• Relevant experience
• Strong advisory board with extensive experience in Biotech start-up

35 LIKES

READ MORE

SHARE

HEMISPHERE PHARMACEUTIC...

Our mission at Hemisphere Pharmaceuticals is to provide customers suffering from neurodegenerative diseases with medications that prevent the symptoms, delay the progression, or cure their illness. We seek to offer these medications as treatment options that are competitively priced with current therapy options

35 LIKES

READ MORE

SHARE

UNIVERSITY OF PENNSYLVANI...

Autoimmune diseases are chronic and often incurable disorders with few effective treatments. Among these treatments are powerful immunosuppressive drugs such as Tysabri - the last line of hope for Crohn's Disease and Multiple Sclerosis patients. However, these drugs render patients at risk for fatal infections such as

6 LIKES

READ MORE

SHARE

UNIVERSITY OF PENNSYLVANI...

Executive Summary: NeuroExP is a startup with its founding members at the University of Pennsylvania in Philadelphia. The company is based on the intellectual property owned by the US Dept. of Health and Human Services, surrounding its Blast-induced Neurotrauma (BINT) simulator. The device allows for study of cellular response in mild

243 LIKES

READ MORE

SHARE

CAMBRIDGE CCN - 9.A

Our company, angioClast, will provide a new approach for clinicians to treat brain cancer. Using 13 newly patented markers of cancer-specific blood vessels, identified by Dr St Croix of the NCI Center for Cancer Research, we will develop clinical grade antibodies to carry drugs directly to kill cancer blood vessels and prevent cancer progression. A handful

116 LIKES

READ MORE

SHARE

UPENN - 8.A

Mission: Neurono aims to exclude ~8,600 potential US brain cancer patients from undergoing unnecessary brain biopsies annually by leveraging a new proprietary diagnostic blood test. Specifically, JK Neurotech has developed an assay that detects levels of Anti-TNF Induced Apoptosis (ATA) protein, which is released specifically by glioblastoma

70 LIKES

READ MORE

SHARE

HKCCN - 10.C

About Orphaceuticals Orphaceuticals Ltd. is an anti-cancer company specializing in Neurofibromatosis Type 1 (NF-1) therapeutics. The company is developing an orphan drug to treat Malignant Peripheral Nerve Sheath Tumors (MPNSTs) caused by NF-1 utilizing the compound Schwellenfurtherin A (SA). The management of the project boasts a mix of

103 LIKES

READ MORE

SHARE

WASHINGTON UNIVERSITY IN ...

ChromiScan: Executive Summary ChromiScan



116 LIKES

READ MORE

SHARE

JOHNS HOPKINS UNIVERSITY ...

Cogentis Therapeutics is developing a breakthrough



Amyloid beta plaques



116 LIKES

READ MORE

SHARE

MEDICAL COLLEGE OF WISCO...

Executive Summary: Angio360 Diagnostics



Blood Diagnostic Panel

Imaging Diagnostic Panel

116 LIKES

READ MORE

SHARE

develops and manufactures next-generation MRI contrast agents enabling imaging of multiple biomarkers simultaneously. Our first focus is Alzheimer's disease, a global aging illness. The current contrast agents can only detect one biomarker and thus causing a high false positive

 47 LIKES

[READ MORE](#)

[SHARE](#)

therapeutic for Alzheimer's disease, a severe neurodegenerative condition that involves progressive loss of memory and other brain functions, eventually resulting in death. The disease affects an estimated 30-40 million people globally, a figure that will double by 2030, and is the 6th

 131 LIKES

[READ MORE](#)

[SHARE](#)

specializes in the development of antibody-based products to detect cancer recurrence and tumor vascular health in blood samples and in diagnostic imaging. Utilizing patented biomarkers of tumor-associated blood vessel growth, our AngioTracer Blood Panel, and Imaging Panel detects tumor

 51 LIKES

[READ MORE](#)

[SHARE](#)

UNC CHAPEL HILL - 4.8

We at NeuroNostix believe that a deeper understanding of a patient's underlying physiology is essential to providing that patient with the best possible care. Schizophrenia is often the result of overactive or overexpressed dopamine D2 receptors (D2R); with schizophrenic patients in mind, we are developing highly selective D2R radioligands to

 56 LIKES

[READ MORE](#)

[SHARE](#)